Regeneron Pharmaceuticals stock (US75811P1003): shares hold firm as investors watch large fund purchase and pipeline outlook

Regeneron Pharmaceuticals shares on Nasdaq traded broadly steady on 06/01/2026, with investors in the United States digesting a fresh institutional stake disclosure alongside the company’s established position in high-value biologic therapies.

Regeneron Pharmaceuticals shares on the Nasdaq Global Select Market traded broadly unchanged in early U.S. dealings on 06/01/2026, with the stock hovering near recent levels as investors weighed the company’s mature ophthalmology and immunology franchises against ongoing development spending in the United States, according to exchange data as of 06/01/2026.

The stock traded at around USD 772 on 05/31/2026 on Nasdaq under the ticker REGN, reflecting Regeneron’s position among large U.S. biopharmaceutical names focused on antibody-based therapies, according to Nasdaq data as of 05/31/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Regeneron Pharmaceuticals
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Tarrytown, United States
• Core markets: United States, Europe and other international markets
• Key revenue drivers: Ophthalmology biologics, immunology and inflammation therapies, oncology and rare disease treatments
• Home exchange/listing venue: Nasdaq Global Select Market (REGN)
• Trading currency: USD

Regeneron Pharmaceuticals: core business model

Regeneron Pharmaceuticals develops, manufactures and commercializes biologic medicines rooted in antibody and genetics platforms, with sales today still anchored in ophthalmology, immunology and oncology products that form the bulk of its revenue base.

What banks and research houses say about Regeneron Pharmaceuticals

No verified analyst coverage was identified at the time of publication.

Conclusion

Regeneron Pharmaceuticals’ largely stable share price on Nasdaq on 06/01/2026 underscores how the U.S. market is balancing the company’s entrenched biologic franchises against investment needs across its pipeline. With no newly confirmed analyst targets or major corporate events disclosed on the day, attention remains centered on execution in core indications and the timing of future trial or regulatory updates. For investors tracking U.S.-listed biopharmaceutical leaders, the stock continues to trade as a reference point in large-cap biotechnology given its revenue scale and research footprint.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.